G Masi1, L Salvatore2, L Boni3, F Loupakis2, C Cremolini2, L Fornaro4, M Schirripa2, S Cupini5, C Barbara5, V Safina6, C Granetto7, E Fea7, L Antonuzzo8, C Boni9, G Allegrini10, S Chiara11, D Amoroso12, A Bonetti13, A Falcone2. 1. Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa gl.masi@tin.it. 2. Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa. 3. Clinical Trials Coordinating Center, AOU Careggi/Istituto Toscano Tumori, Firenze. 4. Division of Medical Oncology, Azienda USL 2 di Lucca, Istituto Toscano Tumori, Lucca. 5. Division of Medical Oncology, Azienda USL 6 di Livorno, Istituto Toscano Tumori, Livorno. 6. Division of Medical Oncology, Azienda USL 6 di Livorno, Presidio Ospedaliero di Piombino, Istituto Toscano Tumori, Piombino. 7. Division of Medical Oncology, Ospedale S. Croce e Carle, Cuneo. 8. Division of Medical Oncology 1, Azienda Ospedaliero-Universitaria Careggi, Istituto Toscano Tumori, Firenze. 9. Division of Medical Oncology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia. 10. Division of Medical Oncology, Azienda USL 5 di Pisa, Ospedale Felice Lotti, Istituto Toscano Tumori, Pontedera. 11. Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria San Martino-Istituto Nazionale Ricerca Cancro, Genova. 12. Division of Medical Oncology, Ospedale della Versilia, Istituto Toscano Tumori, Lido di Camaiore. 13. Division of Medical Oncology, AULSS 21 Legnago, Ospedale Mater Salutis, Legnago, Italy.
Abstract
BACKGROUND: The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the efficacy of continuing or reintroducing bevacizumab in combination with second-line chemotherapy after progression to bevacizumab-based first-line therapy. PATIENTS AND METHODS: In this phase III study, patients with mCRC treated withfluoropyrimidine-based first-line chemotherapy plus bevacizumab were randomized to receive in second-line mFOLFOX-6 or FOLFIRI (depending on first-line regimen) with or without bevacizumab. The primary end point was progression-free survival. To detect a hazard ratio (HR) for progression of 0.70 with an α and β error of 0.05 and 0.20, respectively, 262 patients were required. RESULTS: In consideration of the results of the ML18147 trial, the study was prematurely stopped. Between April 2008 and May 2012, a total of 185 patients were randomized. Bevacizumab-free interval was longer than 3 months in 43% of patients in chemotherapy alone arm and in 50% of patients in the bevacizumab arm. At a median follow-up of 45.3 months, the median progression-free survival was 5.0 months in the chemotherapy group and 6.8 months in the bevacizumab group [adjusted HR = 0.70; 95% confidence interval (CI) 0.52-0.95; stratified log-rank P = 0.010]. Subgroup analyses showed a consistent benefit in all subgroups analyzed and in particular in patients who had continued or reintroduced bevacizumab. An improved overall survival was also observed in the bevacizumab arm (adjusted HR = 0.77; 95% CI 0.56-1.06; stratified log-rank P = 0.043). Responses (RECIST 1.0) were similar in the chemotherapy and bevacizumab groups (17% and 21%; P = 0.573). Toxicity profile was consistent with previously reported data. CONCLUSIONS: This study demonstrates that the continuation or the reintroduction of bevacizumab with second-line chemotherapy beyond first progression improves the outcome and supports the use of this strategy in the treatment of mCRC. ClinicalTrials.gov number: NCT00720512.
RCT Entities:
BACKGROUND: The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the efficacy of continuing or reintroducing bevacizumab in combination with second-line chemotherapy after progression to bevacizumab-based first-line therapy. PATIENTS AND METHODS: In this phase III study, patients with mCRC treated with fluoropyrimidine-based first-line chemotherapy plus bevacizumab were randomized to receive in second-line mFOLFOX-6 or FOLFIRI (depending on first-line regimen) with or without bevacizumab. The primary end point was progression-free survival. To detect a hazard ratio (HR) for progression of 0.70 with an α and β error of 0.05 and 0.20, respectively, 262 patients were required. RESULTS: In consideration of the results of the ML18147 trial, the study was prematurely stopped. Between April 2008 and May 2012, a total of 185 patients were randomized. Bevacizumab-free interval was longer than 3 months in 43% of patients in chemotherapy alone arm and in 50% of patients in the bevacizumab arm. At a median follow-up of 45.3 months, the median progression-free survival was 5.0 months in the chemotherapy group and 6.8 months in the bevacizumab group [adjusted HR = 0.70; 95% confidence interval (CI) 0.52-0.95; stratified log-rank P = 0.010]. Subgroup analyses showed a consistent benefit in all subgroups analyzed and in particular in patients who had continued or reintroduced bevacizumab. An improved overall survival was also observed in the bevacizumab arm (adjusted HR = 0.77; 95% CI 0.56-1.06; stratified log-rank P = 0.043). Responses (RECIST 1.0) were similar in the chemotherapy and bevacizumab groups (17% and 21%; P = 0.573). Toxicity profile was consistent with previously reported data. CONCLUSIONS: This study demonstrates that the continuation or the reintroduction of bevacizumab with second-line chemotherapy beyond first progression improves the outcome and supports the use of this strategy in the treatment of mCRC. ClinicalTrials.gov number: NCT00720512.
Authors: S Bazarbashi; A M Hakoun; A M Gad; M A Elshenawy; A Aljubran; A M Alzahrani; A Eldali Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677
Authors: Jaafar Bennouna; Sandrine Hiret; Aurelie Bertaut; Olivier Bouché; Gael Deplanque; Christian Borel; Eric François; Thierry Conroy; François Ghiringhelli; Gaëtan des Guetz; Jean-François Seitz; Pascal Artru; Mohamed Hebbar; Trevor Stanbury; Marc G Denis; Antoine Adenis; Christophe Borg Journal: JAMA Oncol Date: 2019-01-01 Impact factor: 31.777
Authors: Madelon Q Wentink; Tilman M Hackeng; Sebastien P Tabruyn; Wouter C Puijk; Klaus Schwamborn; Daniele Altschuh; Rob H Meloen; Teun Schuurman; Arjan W Griffioen; Peter Timmerman Journal: Proc Natl Acad Sci U S A Date: 2016-10-17 Impact factor: 11.205
Authors: Francesco Montagnani; Greta Di Leonardo; Mariasimona Pino; Simona Perboni; Angela Ribecco; Luisa Fioretto Journal: J Transl Int Med Date: 2017-03-31
Authors: Simone Mocellin; Zora Baretta; Marta Roqué I Figuls; Ivan Solà; Marta Martin-Richard; Sara Hallum; Xavier Bonfill Cosp Journal: Cochrane Database Syst Rev Date: 2017-01-27
Authors: Eric Van Cutsem; Florence Joulain; Paulo M Hoff; Edith Mitchell; Paul Ruff; Radek Lakomý; Jana Prausová; Vladimir M Moiseyenko; Guy van Hazel; David Cunningham; Dirk Arnold; Hans-Joachim Schmoll; Albert J Ten Tije; Joseph McKendrick; Hendrik Kröning; Yves Humblet; Cristina Grávalos; Solenn Le-Guennec; Michael Andria; Emmanuelle Dochy; Raghu L Vishwanath; Teresa Macarulla; Josep Tabernero Journal: Target Oncol Date: 2016-06 Impact factor: 4.493